[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Repligen Corp (RGEN)

Repligen Corp (RGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
3 Hyped Up Stocks We Keep Off Our Radar

3 Hyped Up Stocks We Keep Off Our Radar

SWK : 100.02 (+1.18%)
NBTB : 52.09 (+0.40%)
RGEN : 181.13 (+0.47%)
Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks

Unpacking Q2 Earnings: Repligen (NASDAQ:RGEN) In The Context Of Other Drug Development Inputs & Services Stocks

RGEN : 181.13 (+0.47%)
2 Growth Stocks to Add to Your Roster and 1 We Avoid

2 Growth Stocks to Add to Your Roster and 1 We Avoid

SEZL : 119.11 (+1.44%)
RGEN : 181.13 (+0.47%)
HCI : 182.52 (+0.49%)
Why Repligen (RGEN) Stock Is Up Today

Why Repligen (RGEN) Stock Is Up Today

RGEN : 181.13 (+0.47%)
Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q2 CY2026

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q2 CY2026

RGEN : 181.13 (+0.47%)
Repligen: Q2 Earnings Snapshot

Repligen: Q2 Earnings Snapshot

RGEN : 181.13 (+0.47%)
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Second quarter revenue of $204 million, a year-over-year increase of 12% as reported and 13% organic GAAP operating income increased 1% year-over-year while adjusted operating income increased 55% ...

RGEN : 181.13 (+0.47%)
Repligen (RGEN) Q2 Earnings: What To Expect

Repligen (RGEN) Q2 Earnings: What To Expect

RGEN : 181.13 (+0.47%)
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of BioLife Solutions ...

BLFS : 37.10 (+0.35%)
RGEN : 181.13 (+0.47%)
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know

Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know

TXG : 65.12 (+1.96%)
HIMS : 33.78 (+6.03%)
RGEN : 181.13 (+0.47%)
WST : 353.08 (-0.20%)

Barchart Exclusives

Rocket Lab and AST SpaceMobile Are Priced for the Big Bang. One Space Stock Already Delivered.
Two space stocks are priced for a perfect future. A third is already cashing checks. Here's what Rocket Lab, AST SpaceMobile, and Karman really cost. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.